jueves, 29 de septiembre de 2016

GSK & Google: En busca de medicinas bioelectrónicas...


GlaxoSmithKline is teaming up with Google's parent company Alphabet to create a new company focused on developing bioelectronic medicines. 

The UK drugs giant is setting up a joint venture - Galvani Bioelectronics - with Alphabet division Verily Life Sciences to enable research, development and commercialisation of new products in this relatively new field, which involves the use of miniaturised, implantable devices to modify electrical signals that might help tackle chronic diseases. 

Each of its parent companies will contribute existing intellectual property rights and an investment of up to £540 million over seven years, subject to successful completion of various discovery and development milestones, giving GSK a 55 percent stake and Verily a 45 percent share in the business. 

Galvani will be headquartered in the UK at GSK's global R&D centre at Stevenage, with a second research hub at Verily's facilities in South San Francisco, and the firm will initially take on around 30 expert scientists, engineers and clinicians, as well as stream funds into a broad range of collaborations with both parent companies, academia and other R&D organisations.


Initial work will centre on establishing clinical proofs of principle in inflammatory, metabolic and endocrine disorders, including type II diabetes, where substantial evidence already exists in animal models; and developing associated miniaturised, precision devices. 

"This agreement with Verily to establish Galvani Bioelectronics signals a crucial step forward in GSK's bioelectronics journey, bringing together health and tech to realise a shared vision of miniaturised, precision electrical therapies," noted Moncef Slaoui, GSK's Chairman of Global Vaccines. "Together, we can rapidly accelerate the pace of progress in this exciting field, to develop innovative medicines that truly speak the electrical language of the body.

Kris Famm, GSK's vice president of Bioelectronics R&D, will lead the new company. (Ver)
Publicar un comentario en la entrada